Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rapoport, Aaron P
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study	Recruiting	1	250	Europe, Canada, US, RoW	ADP adoptive cell therapy	Adaptimmune	Neoplasms	04/32	04/32
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)